106 related articles for article (PubMed ID: 17257470)
1. Strategies to improve tolerability of rivastigmine: a case series.
Venkatesh K; Bullock R; Akbaş A
Curr Med Res Opin; 2007 Jan; 23(1):93-5. PubMed ID: 17257470
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
3. Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances.
Scarzella L; Costanza A; Vastola K
Funct Neurol; 2007; 22(2):101-4. PubMed ID: 17637213
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic rationale for the rivastigmine patch.
Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of rivastigmine in routine clinical practice.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
[TBL] [Abstract][Full Text] [Related]
6. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
7. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
8. [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study].
Agüera-Ortiz LF; Ramos-García M; Gobartt AL;
Rev Neurol; 2008 May 1-15; 46(9):517-24. PubMed ID: 18446692
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Starr JM
J Am Geriatr Soc; 2007 May; 55(5):800-1. PubMed ID: 17493206
[No Abstract] [Full Text] [Related]
11. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
Lee JH; Sevigny J
Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
[TBL] [Abstract][Full Text] [Related]
12. Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.
Segers K; Cytryn E; Surquin M
J Clin Psychopharmacol; 2012 Jun; 32(3):412-5. PubMed ID: 22544007
[TBL] [Abstract][Full Text] [Related]
13. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
14. Rivastigmine associated hyponatremia in an older patient with Alzheimer's disease.
Naharci IM; Bozoglu E; Karadurmus N; Karaman M; Kurt O; Doruk H
J Am Geriatr Soc; 2011 Jul; 59(7):1351-2. PubMed ID: 21751972
[No Abstract] [Full Text] [Related]
15. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
16. Acute dystonic reaction with rivastigmine.
Dhikav V; Anand KS
Int Psychogeriatr; 2013 Aug; 25(8):1385-6. PubMed ID: 23561545
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine patches: line extension. No therapeutic advantage and less convenient than capsules.
Prescrire Int; 2009 Feb; 18(99):19. PubMed ID: 19391277
[No Abstract] [Full Text] [Related]
18. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
Burian R
MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
[No Abstract] [Full Text] [Related]
19. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
20. High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.
Riepe MW
J Clin Psychiatry; 2014 Mar; 75(3):288. PubMed ID: 24717382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
